# Antipsychotic Discontinuation in Alzheimer's Disease

> **NCT00417482** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 180 (actual)

## Conditions studied

- Alzheimer Disease
- Psychotic Disorders
- Agitation
- Aggression

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00417482
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2013-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417482, "Antipsychotic Discontinuation in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00417482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*